REFERENCES
- Mitchell-Heggs C AW, Conway M, Cassar J. Herbal medicine as a cause of combined lead and arsenic poisoning. Hum Exp Toxicol 1990; 9: 195–196
- Aposhian H V. DMSA and DMPS—water soluble antidotes for heavy metalpoisoning. Ann Rev Pharmacol Toxicol 1983; 23: 193–215
- Aposhian H V, Aposhian M M. Meso-2,3-dimercaptosuccinic acid: Chemical, pharmacologicaland toxicological properties of an orally effective metal chelating agent. Ann Rev Pharmacol Toxicol 1990; 30: 279–306
- Aposhian H V, Maiorino R M, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically usefulchelating agents. Toxicology 1995; 97: 23–38
- Angle C R. Childhood lead poisoning and its treatment. Ann Rev Pharmacol Toxicol 1993; 32: 409–434
- Asiedu P, Moulton T, Blum C B, et al. Metabolism of meso-2,3-dimercaptosuccinic acid in lead-poisonedchildren and in normal adults. Environmental Health Perspectives 1995; 103: 734–739
- McGown E L, Tillotson J A, Knudsen J J, Dumlao C R. Biological behavior and metabolic fate of the BAL analoguesDMSA and DMPS. Proc West Pharmacol Soc 1984; 27: 169–176
- Friedheim E AH, DaSilva J R, Martins A V. Treatment of schistosomiasis mansoni with antimony a,á-dimercapto-potassiumsuccinate (TWSb). Am J Trop Med Hyg 1954; 3: 714–727
- Wang S C, Ting K S, Wu C C. Chelating therapy with Na-DMS in occupational lead and mercuryintoxications. Chinese Med J 1965; 84: 437–439
- Graziano J H, Siris E S, Lolacono N, Silverberg S J, Turgeon L. 2,3-dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharm Ther 1985; 37: 431–438
- Graziano J H, Lolacono N J, Meyer P. Dose response study of oral 2,3-dimercaptosuccinic acid in childrenwith elevated blood lead concentrations. J Ped 1988; 113: 751–757
- Domingo J L, Paternain J L, Llobet J M, Corbella J. Developmental toxicity of subcutaneously administered meso-2,3-dimercaptosuccinicacid in mice. Fundam Appl Toxicol 1986; 11: 715–722
- Chisolm J J. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoningin children. J Toxicol Clin Toxicol 1992; 30: 493–504
- Bannon D I, Murashchik C, Zapf C R, Farfel M R, Chisolm J J. Graphite furnace atomic absorption spectroscopic measurementof blood lead using matrix-matched standards. Clin Chem 1994; 40: 1730–1734
- Chisolm J J, Thomas D J, Hamill T. Erythrocyte porphobilinogen synthase activity as an indicatorof lead exposure in children. Clin Chem 1895; 31: 601–605
- Ravin H A. An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 1961; 58: 161–168
- Maiorino R M, Bruce D C, Aposhian V H. Determination and metabolism of dithiol chelating agents. Toxicol Appl Pharm 1989; 97: 338–349
- Crofton P M. What is the cause of benign transient hyperphosphatasemia? Astudy of 35 cases. Clin Chem 1988; 34: 335–340
- Lee B K, Schwartz B S, Stewart W, Ahn K D. Provocative chelation with DMSA and EDTA: Evidence for differentialaccess to lead storage sites. Occup Environ Med 1995; 52: 13–19
- Woolard D, Calascan C, Smith D. Effects of succimer on the diuresis of essential metals in aprimate. Model of childhood lead poisoning. The Toxicologist 1999; 48: 349
- Chisolm J J, Thomas D J. Use of 2,3-dimercaptopropane-1-sulfonate in treatment of leadpoisoning in children. J Pharm Exp Ther 1985; 235: 665–669
- Chisolm J J. The use of chelating agents in the treatment of acute and chroniclead intoxication in children. J Ped 1968; 73: 1–38
- Grandjean P, Jacobsen I A, Jorgensen P J. Chronic lead poisoning treated with dimercaptosuccinic acid. Pharm Tox 1991; 68: 266–269
- Mann K V, Travers J D. Succimer, an oral lead chelator. Clin Pharm 1991; 10: 914–922